Havemeyer Place LP Invests $800,000 in DexCom, Inc. $DXCM

Havemeyer Place LP acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,053 shares of the medical device company’s stock, valued at approximately $800,000.

Other large investors also recently made changes to their positions in the company. CVA Family Office LLC increased its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. MCF Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth $32,000. ORG Partners LLC increased its position in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares in the last quarter. Spire Wealth Management increased its position in shares of DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after acquiring an additional 305 shares in the last quarter. Finally, Aventura Private Wealth LLC acquired a new stake in shares of DexCom in the fourth quarter worth $43,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares in the company, valued at approximately $7,326,353. This represents a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 42,694 shares of company stock worth $3,029,267. 0.28% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DXCM shares. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Monday, May 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a report on Monday, June 1st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, William Blair upgraded DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.04.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $76.62 on Tuesday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The business has a 50 day moving average price of $65.04 and a two-hundred day moving average price of $67.15. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The firm has a market cap of $29.57 billion, a PE ratio of 32.74, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the firm earned $0.32 EPS. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. Sell-side analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.